Hepatitis C virus (HCV) protein synthesis is mediated by a highly conserved internal ribosome entry site (IRES), mostly located at the 59 untranslatable region (UTR) of the viral genome. The translation mechanism is different from that used by cellular cap-mRNAs, making IRESs an attractive target site for new antiviral drugs. The present work characterizes a chimeric RNA molecule (HH363-50) composed of two inhibitors: a hammerhead ribozyme targeting position 363 of the HCV genome and an aptamer directed towards the essential stem-loop structure in domain IV of the IRES region (which contains the translation start codon). The inhibitor RNA interferes with the formation of a translationally active complex, stalling its progression at the level of 80S particle formation. This action is likely related to the effective and specific blocking of HCV IRES-dependent translation achieved in Huh-7 cells. The inhibitor HH363-50 also reduces HCV RNA levels in a subgenomic replicon system. The present findings suggest that HH363-50 could be an effective anti-HCV compound and highlight the possibilities of antiviral agents based on RNA molecules.
INTRODUCTION
Hepatitis C virus (HCV) is an important causal agent of chronic liver disease, a problem that can lead to liver cirrhosis and even hepatocellular carcinoma (Hoofnagle, 1997) . Current therapeutic options based on the use of generic antiviral agents, such as alpha interferon (IFN-a) and ribavirin, do not achieve effective clearance of the viral particles in the majority of patients; this is largely a consequence of the quasispecies structure of the HCV genome (Martell et al., 1992) . This generates a highly variable spectrum of mutants able to escape treatment. The development of new antiviral therapies is therefore a primary goal of current research.
HCV belongs to the family Flaviviridae. Its genetic material exists as a single-stranded (positive orientation) RNA molecule bound to a core protein that forms an icosahedral capsid covered by a lipid envelope (Ishida et al., 2001) . The RNA genome consists of 9600 nt and contains two highly conserved untranslatable regions (UTRs) flanking the coding sequence. These play an essential role in viral translation and replication (Friebe & Bartenschlager, 2002; Friebe et al., 2001; Tsukiyama-Kohara et al., 1992; Wang et al., 1993) . The synthesis of viral proteins is a key initial step that begins with the recruitment of the ribosomal particles by an internal ribosome entry site (IRES) domain located at the 59 UTR and which spans 40 nt downstream of the start codon ( Fig. 1a ; Reynolds et al., 1995; Tsukiyama-Kohara et al., 1992; Wang et al., 1993) . This process clearly differs from that followed by cellular systems. This, along with the high conservation rate of the IRES sequence and its folding, renders the IRES region an excellent target for anti-HCV drugs.
Direct action against the viral genome is one of the most promising antiviral strategies and RNA molecules are excellent candidates for the development of novel drugs (Puerta-Fernández et al., 2003b) . Some of the most exploited approaches include the use of antisense oligonucleotides, ribozymes and siRNAs, all of which have demonstrated their potential to interfere with different steps in the HCV cycle (Romero-Ló pez et al., 2006 and references therein). The main limitation of their use as effective anti-HCV compounds lies in the fact that their action is mediated by sequence complementarity. Thus, point mutations in the target viral region may result in the inactivity of these inhibitory RNAs. In contrast, aptamer activity is determined by sequence complementarity plus the recognition of secondary and tertiary structures. When aptamers bind to these structures, a complex is formed that inhibits the function of the target RNA. The combination of two or more inhibitory RNAs with different activities and/or specificities in an anti-HCV treatment might reduce the appearance of resistant viral variants. In an earlier paper , an in vitro selection procedure was reported for identifying chimeric RNA molecules composed of a catalytic domain and an aptamer domain. Briefly, an RNA pool was constructed based on the previously described hammerhead ribozyme that cleaves HCV RNA at nt 363 (HH363; Lieber et al., 1996) . This carried a 25 nt-long randomized region attached to the 39 end of the ribozyme whose function was to allow effective binding of the putative inhibitor RNAs to the HCV IRES region. The selection method involved two consecutive selection steps: in the first stage, active molecules specifically binding the whole 59 UTR region were selected, and in the second, selective identification of those inhibitory RNAs that retained catalytic activity for processing the HCV IRES was performed. The selected molecules, composed of two functional domains, could represent an original system for preventing the appearance of resistant viral variants. The present paper focuses on the characterization of HH363-50, which has been shown to reduce IRES-mediated translation in vitro by up to 80 % ( Romero-Ló pez et al., 2007) . Both the catalytic domain and the aptamer domain, which targets domain IV of the IRES (Fig. 1) , are functional in this chimeric molecule and their action inhibits IRES function in a liver-derived cell line. Moreover, the cleavage activity of the hammerhead domain reduces viral RNA levels in a replicon system.
METHODS
Cell lines, HCV replicons and culture conditions. The human hepatoma cells (Huh-7 and Huh-7 NS3-39) used in this work were a kind gift from Dr Rafael Aldabe (University of Navarra, Spain). The B76.1/Huh-7 cell line was a generous gift from Dr Amedeo de Tomassi (see De Tomassi et al., 2002) . Cell monolayers were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % heat-inactivated fetal bovine serum (FBS; Invitrogen) and 2 mM L-glutamine (Sigma), at 37 uC in a 5 % CO 2 atmosphere. The culture medium for the Huh-7 NS3-39 cells supporting an HCV subgenomic replicon (genotype 1b) was supplemented with 0.5 mg G-148 ml 21 (Sigma). The subgenomic replicon carries the HCV-IRES of genotype 1b, followed by the neomycin phosphotransferase gene (neo), encephalomyocarditis virus (EMCV)-IRES, the coding sequence for non-structural HCV proteins (NS3-NS5) and the HCV 39 UTR.
DNA templates and RNA synthesis. All RNAs were synthesized by in vitro transcription and purified as previously described (BarrosodelJesus et al., 1999) . DNA templates for the RNAs 59 HCV-356, 59 HCV-691, 59 HCV-691gg, RNA 667, RNA 80, IRES-FLuc and RLuc were obtained as described previously . The plasmid pUCT7pGBV-B 471 FusFLuc was constructed from two independent templates, one of them carrying the GB virus (GBV-B) sequence and the other encoding the gene fluc. These molecules present sequence complementarity that allows it to partially hybridize in a head-to-tail way. The fusion containing the GBV-B IRES plus the Fluc coding sequence was achieved by mixing denatured templates, annealing and extending with DNA polymerase and subsequent amplification with the appropriate primers. Briefly, DNA encoding the GBV-B 471 sequence was obtained by reverse transcription and amplification from total RNA extracted with Trizol (Invitrogen) from B76.1/Huh-7 cells stably supporting GBV-B replication, following the manufacturer's recommendations. cDNA synthesis was performed using 50 ng total RNA by using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). A fraction of the resulting cDNA was used for amplification with primers GBV-B 26 and asGBV-B 448 to produce IRES GBV-B 26-448 (all primer sequences are given in Supplementary Table S1, available in JGV Online). The T7 promoter sequence was attached to the 59 end of IRES GBV-B (T7pGBV-B 471 ) by reamplification of the amplicon with primers T7pGBV-B/BglII and asGBV-B 471. DNA template encoding FLuc was obtained by amplification from plasmid DNA pGL3 Basic (Promega) using primers FusFLuc+GBV-B and asFLuc/BglII to generate FusFLuc. This contains the sequence corresponding to nt 441-471 of the GBV-B genome attached to its 59 end. The T7pGBV-B 471 and GBV-B 471 FusFLuc amplicons were mixed in a 1 : 1 molar ratio at a final concentration of 75 ng ml 21 and PCR-amplified with specific oligonucleotides T7pGBV-B/BglII and asFLuc/BglII to yield the full-length amplicon T7pGBV-B 471 FusFLuc. This was cloned in the BglII sites of the pUC19 vector (Fermentas) to construct plasmid pUCT7pGBV-B 471 FusFLuc. This was digested with BglII and used to synthesize RNA GBV-B 471 FusFLuc. Double-stranded DNA (dsDNA) templates for the HH363-50 and HH363 inhibitory RNAs were obtained as described in . Annealing and extension of specific oligonucleotides was performed as previously described for the generation of the following dsDNA templates: Ap50 was constructed from the hybridization and extension of oligonucleotide T7GG with T7Ap50; oligonucleotide 59T7HH363m and asHH363-50 for the synthesis of HH363m-50; 59HH363is and asHH363-50m to generate HH363-50m; and 59T7HH363m with asHH363-50m for HH363m-50m. RNA molecules employed in the inhibition assays were obtained as described previously (Romero-Ló pez et al., 2007) .
Binding assays. Binding assays were performed by incubating 2 nM 32 P 59-end-labelled inhibitor, HH363-50 or HH363, with increasing concentrations of the RNA substrate 59HCV-691gg in the presence of 16 TMN buffer (10 mM Tris/acetate pH 7.5, 10 mM magnesium acetate, 100 mM sodium chloride). The resulting complexes were resolved, analysed and quantified as described previously . The dissociation constant (K d ) values were calculated using Sigma Plot 8.02 software according to the equation -Fernández et al., 2005) , where y is the percentage of complexed inhibitory RNA, B max is the amplitude of the reaction and x is the concentration of the substrate RNA 59HCV-691gg.
RNA cleavage assays. Cleavage reactions were performed under single-turnover conditions as described previously (Pérez-Ruiz et al., 1999) . Briefly, 2 nM internally labelled 59HCV-691 substrate and a 50-fold excess of inhibitor RNAs were denatured in cleavage buffer (50 mM Tris/HCl pH 7.5, 10 mM MgCl 2 ). The reaction was initiated by mixing the substrate and the catalytic RNAs, and incubating at 37 uC for 120 min. Aliquots were removed at different times and cleavage was quenched by the addition of an equal volume of loading buffer. Cleavage products were resolved in 4 % denaturing polyacrylamide gels. Data were fitted by nonlinear regression to the equation y~y 0 za(1{e {kobst ), where y represents the percentage cleavage, a is the amplitude of the cleavage reaction, t corresponds to the time and k obs is the rate constant.
RNA-RNA interaction probing assays. RNA probing assays of the HH363-50-HCV-691 complex were achieved with either 32 P 59-endlabelled chimeric inhibitor or substrate RNA. Complexes were constructed as described by , by incubating 50 fmol 32 P 59-end-labelled RNA (~200 c.p.m.) with 10 pmol non-labelled target molecule (HCV-691 for the chimeric inhibitor assay or HH363-50 for IRES probing). Control reactions were performed in the presence of an equal amount of a non-related RNA (RNA 667 or tRNA). Cleavage reactions were initiated by the addition of RNase T1 (0.1 units), RNase A (0.2 ng) or Pb 2+ acetate (30 mM), and incubated at 30 uC for 2, 20 and 7 min, respectively. Reactions were stopped by the addition of 100 mM EDTA followed by phenol extraction. RNAs were precipitated with ethanol and analysed in high-resolution denaturing polyacrylamide gels (6-20 %).
In vitro translation assays. IRES-FLuc and RLuc mRNAs were translated in either the absence or presence of the inhibitor RNAs as described previously (Romero-Ló pez et al., 2007) . Protein products were resolved in 12.5 % (w/v) denaturing polyacrylamide gels. The IC 50 values were calculated with SigmaPlot 8.02 software using the equation y~100=(1z10 logIC 50 {x ) (Romero-Ló pez et al. , 2007) , where y max is the maximum percentage of relative FLuc synthesis, IC 50 is the inhibitor concentration that produces 50 % of the maximum observed effect and x is the inhibitor concentration.
Ribosome-IRES complex assembly assays. The identification of 48S and 80S particles was performed as reported previously (Ray & Das, 2004; Romero-Ló pez et al., 2007) . Briefly, 40 nM 32 P-internally labelled RNA IRES-FLuc (~200 000 d.p.m.) was incubated with 5 mM inhibitor RNAs and 5 ml translation reaction mix. The reactions were incubated at 30 uC for 20 min, stopped on ice and then diluted to 150 ml with gradient buffer (20 mM Tris/HCl pH 7.5, 100 mM KCl, 3 mM MgCl 2 , 1 mM DTT). Ribosomal complexes were resolved in a continuous 10-30 % linear sucrose gradient by ultracentrifugation at 30 000 r.p.m. for 4 h. Fractions of 500 ml were collected from the top of the gradient and their radioactivity was measured using a QuickCount QC-4000/XER Benchtop Radioisotope Counter (Bioscan).
Transfection assays. Intracellular activity of the inhibitor RNAs in a human hepatoma cell line (Huh-7) was evaluated as previously described (Romero-Ló pez et al., 2007) . Briefly, a mixture containing 1.5 mg IRES-Fluc RNA and RLuc mRNA was co-transfected with increasing amounts of inhibitory RNA using TransFectin (Bio-Rad). Eighteen hours after transfection, cells were harvested and Firefly and Renilla luciferase activities were determined using the Dual-Luciferase reporter assay system (Promega).
Analysis of the inhibitory effect on HCV replication was performed by transfection in a subgenomic replicon system, Huh-7 NS3-39 (Larrea et al., 2006; Lohmann et al., 1999) . Cell monolayers were cultured in 1.5 cm diameter dishes for 24 h up to 70-80 % confluency. Inhibitor or control RNAs (7 mg) were subsequently transfected with TransFectin. Twenty hours after transfection, the cells were harvested and processed for analysis.
Quantification of the HCV RNA replicon. Intracellular levels of the positive strand of HCV subgenomic replicon RNA were detected by quantitative RT-PCR and normalized to those obtained for GAPDH cellular mRNA. Total cellular RNA was extracted using Trizol, as recommended by the manufacturer. DNase I-treated RNA (20 ng) was reverse-transcribed with the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Briefly, total RNA was hybridized with a molar excess of random primers by denaturation at 95 uC and slow cooling. MultiScribe reverse transcriptase was then added to a final concentration of 0.5 U ml 21 and extension of the cDNA was performed in two steps: slow extension at 16 uC for 30 min followed by fast extension at 42 uC for 30 min. The reverse transcriptase was heat-inactivated at 85 uC for 5 min; 3/20 of the cDNA mix was then diluted with the Taqman Gene Expression Master Mix (Applied Biosystems) and HCV cDNA was amplified by PCR over 40 cycles (15 s at 94 uC and 1 min at 60 uC) with specific oligonucleotides targeting the IRES region (C-149 and C-342) (Martell et al., 1999) . The fluorogenic Taqman probe (FT-275) was added to the PCR mixture to a final concentration of 150 nM (Martell et al., 1999) . For GAPDH quantification, 3/20 of the reverse transcription reaction was mixed with the Taqman Gene Expression Master Mix and amplification was performed using the Human GAPD (GAPDH) Endogenous Control kit (Applied Biosystems). Temperature conditions were the same as those established for the amplification of HCV RNA. PCRs were performed using an ABI PRISM 7000 Sequence Detector System and data were analysed using ABI PRISM 7000 SDS software v.1.1 (both from Applied Biosystems).
RESULTS

HH363-50 binds and cleaves the HCV-IRES in vitro
The inhibitory RNA HH363-50 consists of a hammerhead ribozyme (HH363) attached to an aptamer (Ap50) with complementary sequences to domain IV of the HCV-IRES ( Fig. 1 ; . Cleavage and binding assays of the HCV-IRES RNA were performed to confirm that both activities were present in the chimeric molecule.
The binding capacity of HH363-50 for the HCV-IRES was evaluated using HCV-691gg as the RNA substrate (Romero-Ló pez et al., 2007) . This contains the first 691 nt of the HCV-1b genome with two substitutions (U 362 AG and C 363 AG) that abolish its cleavage by the catalytic domain. The inhibitory RNA (2 nM) was assayed against different concentrations of HCV-691gg. These titration assays were used to calculate the K d , which directly reflects the binding affinity. HH363-50 had a K d of 5.47 nM (Table 1) , indicating a high affinity for the IRES.
To determine the efficiency of the cleavage activity of HH363-50 on HCV-IRES RNA, an RNA molecule containing the first 691 nt of the HCV-1b genome (HCV-691; Romero-Ló pez et al., 2005) was used as a target. Cleavage reactions were performed under single-turnover conditions and k obs values were determined. HH363-50 effectively cleaved the HCV-691 substrate, with a k obs value of 0.042 min 21 (Table 1) .
These results show that cleavage and binding activities are retained in the chimeric molecule.
HCV-IRES domain IV is the target of HH363-50
Sequence analysis of HH363-50 identified a motif in the apical loop of the aptamer domain, A 48 UCAUGG 54 , complementary to the apical loop of domain IV in the HCV-IRES ( Fig. 1 ; ). An interaction involving both motifs seems plausible. RNase and lead probing assays of the two interacting molecules and the resulting complex were undertaken to examine this hypothesis.
To identify the interacting residues in the IRES region, a 32 P 59-end-labelled RNA containing the first 356 nt of the HCV-1b genome (59HCV-356; Romero-Ló pez et al., 2005) was subjected to partial digestion with nucleases (RNase T1 and RNase A) and lead, in the presence of a molar excess of tRNA. Under these conditions, cleavage mainly involved single stranded residues (G nucleotides for RNase T1, C or U for RNase A and any nucleotide for lead treatment). The degradation map of the 59 UTR region resembled that previously described, in which domain IV adopts a stem- Values are the mean (±SD) of four independent assays. K d , dissociation constant; B max , amplitude of the binding reaction; k obs , cleavage rate constant; a, amplitude of the cleavage reaction.
Binding
Cleavage loop structure with loop residues that are highly sensitive to hydrolysis ( Fig. 2 ; Kieft et al., 1999) . The presence of HH363-50 induced a change in this cleavage pattern, making nucleotides located at the apical loop of domain IV clearly resistant to cleavage (Fig. 2) . This undoubtedly reflects the participation of domain IV in the binding of HH363-50 to HCV-IRES.
The secondary structure of HH363-50 was then analysed to identify the nucleotides involved in its association with domain IV. The inhibitor RNA was 59-end labelled with 32 P and incubated with a molar excess of a non-related RNA (RNA 667; Romero-Ló pez et al., 2007). Partial digestion reactions with RNase T1 and lead were essentially performed as above and the resulting degradation pattern (Fig. 3 ) was used for secondary structure prediction using MFold software ( Fig. 1b; Zuker, 2003) . This analysis showed that both the hammerhead and aptamer domains folded independently, conserving their structural identity (Figs 1b and 4) . The aptamer region adopted a typical stem-loop structure in which the motif A 48 UCAUGG 54 was clearly exposed in the apical loop (Figs 1b and 3 ). In the presence of the RNA substrate HCV-691gg, this loop became resistant to degradation by both RNase T1 and lead (Fig. 3) , confirming its implication in the interaction with the HCV-IRES. This complex could be stabilized by the presence of the non-canonical GA pair (A 48 -G 54 ) located at the base of the aptamer loop, as has been described for other loop-loop interactions (Ducongé & Toulmé, 1999; Lebars et al., 2007) .
Taken together, these results firmly sustain the initial hypothesis that domain IV of the IRES is the anchoring site for HH363-50.
In vitro inhibition of IRES function by HH363-50
The strong inhibitory effect of HH363-50 on IRES function was reported in earlier work (Romero-Ló pez et al., 2007).
In vitro translation assays were performed to study this further. Two RNA molecules were used as templates: one encoding the HCV-IRES that fuses to the FLuc coding sequence at its 39 end and one coding for the RLuc protein, which is translated in an IRES-independent way (used as an internal control). Several concentrations of HH363-50 were tested, with a molar IRES-FLuc : HH363-50 ratio from 4 : 1 to 1 : 125. Strong and dose-dependent inhibition (up to 80 %) of IRES function was induced by HH363-50 (IC 50 51.13 mM; Fig. 4 and Table 2 ). This activity did not affect cap-dependent translation since the RLuc levels were not altered at the highest inhibitor concentration analysed (,5 %, data not shown). Similar assays were performed with the EMCV-IRES fused to FLuc to further confirm the specificity of the HH363-50 inhibitory activity. The results show that HH363-50 did not significantly affect EMCV-IRES-dependent translation (Fig. 4) , thus demonstrating the specificity of the inhibitor.
Three mutants were constructed to investigate the contribution of individual HH363-50 functional domains to the overall inhibitory effect (Figs 1b and 4): HH363m-50 ). Specific cleavage products were resolved in 6 % high resolution denaturing polyacrylamide gels. The right panel corresponds to electrophoresis under conditions aimed to resolve larger fragments. Nucleotides resistant to nucleases and lead treatment are boxed. T1L, T1 cleavage ladder.
Anti-HCV inhibitor RNA
with a point mutation in the catalytic core of the hammerhead ribozyme that abolishes its cleavage activity; HH363-50m which contains four point mutations at the aptamer interacting site that impair its binding capacity; and HH363m-50m that combines both modifications and renders a completely inactive variant. Of note, these substitutions did not affect the secondary structure of the inhibitor RNA (data not shown). In vitro inhibition assays showed that the single mutants HH363m-50 and HH363-50m interfered with IRES function, though their effect was significantly weaker than that exerted by HH363-50 at every concentration assayed. The IC 50 values were fourand fivefold higher, respectively, than for HH363-50 (Fig. 4 and Table 2 ). Translation assays in the presence of HH363m-50m domains resulted in an almost imperceptible reduction in HCV-IRES function.
These results suggest that the fully active molecule is required for the most potent inhibitory effect to be obtained.
Interference with 80S complex assembly
Domain IV of the HCV-IRES fulfils an essential role in the initiation of translation. Besides its static function as the bearer of the start codon, its participation has been also proposed in the positioning of the ribosome P site at the translation start codon (Ji et al., 2004; Lytle et al., 2002) . Hence, the effect of the interaction between domain IV and HH363-50 on the ribosomal complex assembly was analysed. In vitro translation assays were performed using an internally 32 P-labelled IRESFLuc substrate and RLuc RNA. Translational 48S and 80S complexes were detected by sucrose density gradient ultracentrifugation. This gave a reproducible profile in which two well-defined peaks were detected, corresponding to 48S and 80S particles (Fig. 5) . In the presence of HH363-50, 80S complex formation was severely blocked, indicating that the chimeric inhibitor could interfere with the IRES structural rearrangements that arose prior to the positioning of the start codon at the P site, blocking the evolution of the ternary complex to the 80S particle. The requirement for both functional domains for interfering with the formation of the 80S complex was investigated further. While an evident reduction in the level of 80S particles in the presence of HH363m-50 was detected, only a slight decline occurred when HH363-50m was added (Fig. 5) . This suggests that the main contribution to interference with the translational complex assembly is made by the aptamer domain, though cleavage activity by the hammerhead motif may also have a role at this point. No significant changes were observed in the sedimentation profile in the presence of HH363m-50m (Fig. 5) , confirming that the inhibitory function is a characteristic property of the cleavage and binding activities themselves.
Inhibition of IRES-dependent translation in a cell culture system
In order to evaluate the intracellular activity of HH363-50, Huh-7 cells were co-transfected with a mixture containing IRES-FLuc, RLuc and different amounts of HH363-50 RNAs. We observed efficient inhibition of IRES-dependent translation, with a reduction in FLuc levels of around 50 % at the maximum concentration tested (Fig. 6a) . No significant changes were observed in the cap-dependent translation (,5 %; data not shown). To corroborate the specificity of HH363-50 for the HCV-IRES, inhibition assays were performed using the FLuc RNA fused at its 59 end to the GBV-B IRES. GBV-B is a hepatotropic flavivirus distantly related to HCV (Muerhoff et al., 1995) . Both flaviviruses have obvious similarities in their genome organization, and the 59 and 39 UTRs show striking structural and functional similarities (Beales et al., 2003; Grace et al., 1999; Honda et al., 1996; Rijnbrand et al., 2000; Sbardellati et al., 1999) . These features render GBV-B an excellent candidate for testing the specificity of anti-HCV molecules. In the present system, GBV-B IRES activity was not significantly altered in the presence of HH363-50 (Fig. 6a) . These results show that the effective and specific inhibition of HCV-IRES occurs in a cell culture system.
The present data suggest that the tested inhibitory RNAs show effective inhibition of IRES function and great target specificity in a hepatoma cell line.
Interference with HCV RNA replication by HH363-50
Finally, the effect of HH363-50 on HCV RNA synthesis was analysed. Huh-7 cells supporting autonomous and stable HCV 1b replication (Huh-7 NS3-39; Larrea et al., 2006; Lohmann et al., 1999) were transiently transfected with the inhibitory RNAs or a non-related small RNA, RNA 80, which acted as a calibrator. Real-time RT-PCR technology was used to quantify the relative amount of HCV RNA with respect to cellular mRNA coding for GAPDH. A significant and reproducible decay of around 50 % in positive HCV RNA molecules was observed at 24 h posttransfection (Fig. 6b) . Further, similar inhibition levels were achieved when HH363-50m was transfected, while the mutation in the hammerhead region (HH363m-50) yielded no significant reduction in HCV RNA levels (Fig. 6b) . This undoubtedly suggests that cleavage activity performed by the catalytic domain is the main factor responsible for the reduction in the amount of HCV RNA in the Huh-7 NS3-39 cell line.
DISCUSSION
Numerous studies have shown that targeting the HCV-IRES region with nucleic acids may be a good antiviral strategy (Romero-Ló pez et al., 2006) . Further, the combination of molecules with different inhibitory features has been proposed as an effective way of preventing the emergence of escape variants (Jarczak et al., 2005; Macejak et al., 2001) . We previously proposed the engineering of inhibitory RNAs carrying several modules of different specificity and activity . This was found to be a valuable alternative for the design of efficient chimeric inhibitory RNAs . The major advantage of this strategy is obtaining inhibitors that target not only conserved sequence motifs but also structural elements that play essential roles in the virus cycle. Therefore, it seems likely that the appearance of resistant viral variants would be reduced with the use of chimeric inhibitors. Moreover, it has been described that inhibitors able to read the 3D folding of their target RNA exhibit increased specificity compared with those that detect only the primary structure (Darfeuille et al., 2006) . HH363-50 is composed of a hammerhead ribozyme that cleaves the HCV genome at nt 363, attached to an aptamer targeting domain IV of HCV-IRES. Both functions remain active in the chimeric inhibitor in vitro, suggesting that the combination of functional domains without significant loss of function is possible. Cleavage of the viral genome by the catalytic motif leads to a reduction in HCV RNA levels in a subgenomic replicon system, while the aptamer activity may interfere with the formation of a productive 80S ribosomal complex. Unfortunately, our results cannot confirm whether a single inhibitory molecule can execute both activities simultaneously. Previous work demonstrates that the whole inhibitory effect exerted by the chimeric molecule cannot be explained as an additive activity of the independent functional domains, since they influence multiple facets of the whole molecule, such as its stability or folding (BarrosodelJesus et al. The present work shows that the inhibitory RNA interacts with high affinity with HCV-IRES through a sequence motif located in an apical loop complementary to the loop of domain IV. Domain IV structure is highly conserved among different isolates and genotypes of HCV, and its stability is inversely correlated with IRES-mediated translation efficiency (Honda et al., 1996) . The existence of alternative conformations could, in fact, favour the anchoring of the aptamer domain through its apical loop. Hairpin loops are excellent sites for initiating and/or establishing intra-or intermolecular interactions through Watson-Crick base pairing or non-canonical interactions. Apical loop-apical loop interactions are particularly fast and efficient, making them an effective mechanism for the regulation of multiple biological processes (Brunel et al., 2002) . This finding can be extended to other systems, such as the engineering of aptamers. Many aptamers that exploit this strategy to efficiently bind with their targets have been described . Further, the selection of aptamers targeting domain IV has been described (AldazCarroll et al., 2002) , though in this case, the interacting sequence in the inhibitor was mapped to an internal loop. Recent NMR studies have resolved the structure of a kissing complex between an aptamer and its target, showing that the interaction is stabilized by the presence of the GA pair at the base of the aptamer loop. This increases the stacking at the stem-loop junction, which is crucial for the formation of a stable complex (Ducongé & Toulmé, 1999; Lebars et al., 2007) . The present results support the assumption in which exposed complementary sequences interact, leading to the formation of an HH363-50-domain IV kissing complex that may be stabilized by the GA pair closing the aptamer loop. This association would block 80S ribosomal particle formation at the stage of the 48S ternary complex.
The inhibitor RNA HH363-50 showed its anti-HCV activity at two levels: IRES-mediated translation and viral RNA synthesis. To detect the inhibitory effect of the IRES function, HH363-50 and the IRES-FLuc RNA were mixed prior to cell transfection. In these conditions, one could assume that a complex between both molecules prior to IRES translation must be pre-formed to get the strongest activity. However, the efficiency exhibited by HH363-50 in a stable HCV replication system makes this unlikely and suggests that the chimeric RNA can act over actively translated viral genomes. We also found that the amounts of chimeric inhibitor employed in these assays differed from those used by other authors to get similar inhibition levels from an HCV-IRES construct (Ray & Das, 2004; Kikuchi et al., 2005; Tallet-Ló pez et al., 2003) . These values cannot be compared since they are dependent on the cell transfection efficiency, the concentration of template RNA used and the levels of trans-acting factors that interact with the IRES.
The inhibitory activity exhibited by HH363-50 highlights the potential to develop inhibitory RNAs for clinical use in combination with classical antiviral treatments, such as IFN-a and ribavirin. HH363-50 should be assayed further over the complete viral cycle to study this possibility in depth. A key point is also the delivery and the intracellular stability of these molecules for putative clinical assays. We observed that around 20 % of the inhibitor RNA HH363-50 still remained at 48 h post-transfection ( Supplementary  Fig. S1 , available in JGV Online). Though this is insufficient for a proper antiviral activity in vivo, it could be significantly improved by the introduction of chemical modifications, such as phosphorothioate, methyl and/or amine substitutions, which provide an increased half-life in serum (Romero-Ló pez et al., 2006) . Furthermore, the use of nanocarriers and molecular conjugates bearing multiple ligands might enhance the transmembrane permeation of the inhibitor RNA and support specific targeting for protein receptors located at the cell surface (Juliano et al., 2008) . Work in these areas is currently underway at our laboratory.
Taken together, the present results, along with those obtained from previous work by our group (Romero-Ló pez et al., 2007) , confirm the success of combining different functional modules to produce chimeric inhibitors. This strategy might be improved further by the simultaneous use of several inhibitors with aptamer domains targeting different regions of the viral genome. This might greatly diminish the appearance of resistant viral variants and could provide the strong inhibition of the viral cycle required in clinical situations. In summary, the present approach provides a promising alternative for the development of new anti-HCV drugs.
